PuSH - Publikationsserver des Helmholtz Zentrums München

Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?

[Obesity treatment: will pharmacotherapies replace metabolic surgery in the future?].

Innere Med. 64, 629-635 (2023)
DOI PMC
Obesity is a chronically progressing disease that represents a major challenge for affected patients, health care professionals and society, since it is highly prevalent and associated with several comorbidities. The treatment of obesity aims at body weight reduction, reducing the burden of comorbidities and weight maintenance after weight loss. To achieve these goals, a conservative treatment strategy is recommended that consists of an energy-reduced diet, increased physical activity and behavioral modifications. If individual treatment targets cannot be achieved by basic treatment, stepwise therapy intensification should be initiated including short-term very low calorie diets, pharmacotherapy or bariatric surgery. However, these treatment approaches differ with respect to average weight loss and other outcomes. There is still a large gap between the efficacy of conservative strategies and "metabolic" surgery that cannot be filled by current pharmacotherapies. However, recent advances in the development of anti-obesity medications could change the positioning of pharmacotherapies in obesity management. Here we discuss whether next-generation pharmacotherapies have the potential to become an alternative to obesity surgery in the future.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Dual Incretin Agonists ; Glucagon-like Peptide‑1 Receptor Agonists ; Semaglutide ; Tirzepatide ; Weight Reduction; Receptor Agonist; Double-blind; Body-weight; Glp-1; Gip; Glucagon; Semaglutide; Placebo; Liraglutide; Tirzepatide
ISSN (print) / ISBN 2731-7080
e-ISSN 2731-7099
Zeitschrift Innere Medizin
Quellenangaben Band: 64, Heft: 7, Seiten: 629-635 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort Heidelbergerplatz 3, Berlin, Germany
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
Institute of Diabetes and Obesity (IDO)